Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations

Author:

Langford Aili V12ORCID,Lin Christine CW3,Bero Lisa4,Blyth Fiona M2,Doctor Jason5,Holliday Simon6,Jeon Yun‐Hee2,Moullin Joanna7,Murnion Bridin28,Nielsen Suzanne9ORCID,Osman Rawa10,Penm Jonathan211,Reeve Emily112,Reid Sharon2ORCID,Wale Janet13,Schneider Carl R2,Gnjidic Danijela2

Affiliation:

1. Centre for Medicine Use and Safety Monash University Melbourne VIC

2. University of Sydney Sydney NSW

3. Institute for Musculoskeletal Health University of Sydney Sydney NSW

4. Center for Bioethics and Humanities University of Colorado Aurora (CO) USA

5. University of Southern California Los Angeles (CA) USA

6. University of Newcastle Newcastle NSW

7. Curtin University Perth WA

8. Western Sydney Local Health District Sydney NSW

9. Monash Addiction Research Centre Monash University Melbourne VIC

10. NPS MedicineWise Sydney NSW

11. Prince of Wales Hospital and Community Health Services Sydney NSW

12. University of South Australia Adelaide SA

13. Melbourne VIC

Abstract

AbstractIntroductionLong term opioids are commonly prescribed to manage pain. Dose reduction or discontinuation (deprescribing) can be challenging, even when the potential harms of continuation outweigh the perceived benefits. The Evidence‐based clinical practice guideline for deprescribing opioid analgesics was developed using robust guideline development processes and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, and contains deprescribing recommendations for adults prescribed opioids for pain.Main recommendationsEleven recommendations provide advice about when, how and for whom opioid deprescribing should be considered, while noting the need to consider each person's goals, values and preferences. The recommendations aim to achieve: implementation of a deprescribing plan at the point of opioid initiation; initiation of opioid deprescribing for persons with chronic non‐cancer or chronic cancer‐survivor pain if there is a lack of overall and clinically meaningful improvement in function, quality of life or pain, a lack of progress towards meeting agreed therapeutic goals, or the person is experiencing serious or intolerable opioid‐related adverse effects; gradual and individualised deprescribing, with regular monitoring and review; consideration of opioid deprescribing for individuals at high risk of opioid‐related harms; avoidance of opioid deprescribing for persons nearing the end of life unless clinically indicated; avoidance of opioid deprescribing for persons with a severe opioid use disorder, with the initiation of evidence‐based care, such as medication‐assisted treatment of opioid use disorder; and use of evidence‐based co‐interventions to facilitate deprescribing, including interdisciplinary, multidisciplinary or multimodal care. Changes in management as a result of these guidelinesTo our knowledge, these are the first evidence‐based guidelines for opioid deprescribing. The recommendations intend to facilitate safe and effective deprescribing to improve the quality of care for persons taking opioids for pain.

Publisher

Wiley

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3